Welcome to Entry Card of Lysosomal Enzymes


Details of RareLED ID Assay_1027
Primary information
GENEGLB1
NUMBER OF ASSAY104
ASSAY IDs411657 338558 402242 289001 265628 241465 241237 241202 241004 240897 40277 40276 40163 40144 1251294 40279 40143 40139 42259 42258 42075 40161 40160 40151 40149 40138 40015 40014 39984 39983 1077402 40168 40165 40162 40154 40141 779311 760667 731130 711097 647241 638944 631854 626416 617950 617949 613054 592302 553256 436558 397848 218553 218551 42257 40150 40013 39985 218547 1329729 1281327 1281321 1281318 1260564 263088 1168106 42253 42252 42251 42240 42239 42066 42062 40007 39996 42255 42241 631855 626414 489730 489425 449878 218549 42254 42238 42249 40008 40006 40005 1322901 1288860 1281317 1272400 1265149 652193 624129 1966 279736 279732 1258853 1225835 1128236 702511 1343457 1343163
Assay Name1. Inhibition of human lysosomal beta galactosidase,2. Inhibition of bovine liver beta-galactosidase assessed as p-nitrophenol release by spectrophotometrically,3. Inhibition of bovine liver beta-galactosidase by spectrophotometry,4. Inhibition of bovine liver beta galactosidase,5. Inhibition of bovine liver beta galactosidase,6. Inhibition of Beta-galactosidase of bovine liver; no inhibition,7. Inhibitory concentration against beta-galactosidase of bovine liver,8. Inhibitory concentration against beta-galactosidase of bovine liver,9. Inhibition of Beta-galactosidase of bovine liver,10. Inhibitory concentration against human beta-galactosidase,11. Inhibition of Beta-galactosidase,12. Concentration required for the inhibition of beta-galactosidase,13. Tested for competitive inhibition of bovine liver beta-galactosidase,14. Concentration that causes 50% inhibition of mammalian cytosolic beta-galactosidase was determined in bovine liver,15. Inhibition of bovine liver beta-galactosidase using 10 mM p-nitrophenyl-beta-D-galactopyranoside as substrate,16. Concentration required to inhibit beta-galactosidase,17. Inhibitory activity against beta-galactosidase in bovine liver,18. Inhibitory activity against beta-galactosidase in bovine liver,19. Inhibitor concentration against Beta-galactosidase from Aspergillus oryzae was tested at a dose of 1 mM,20. Inhibitor concentration against Beta-galactosidase from Aspergillus oryzae,21. Inhibitory concentration against Beta-D-galactosidase of bovine liver,22. Inhibition constant against Beta-galactosidase from Bovine liver; Mixed(Competitive and Non Competitive),23. Inhibition constant (Competitive) against Beta-galactosidase from Bovine liver,24. Inhibitory activity against Beta-galactosidase in bovine liver was determined,25. Inhibitor concentration against Beta-galactosidase from Bovine liver,26. Inhibition constant against Beta-galactosidase from Jack beans; Mixed (Non competitive and competitive),27. Inhibitor concentration against Beta-galactosidase from Jack beans,28. Inhibitor concentration of compound against beta-Galactosidase from Jack beans,29. Inhibition constant against beta-Galactosidase from Aspergillus oryzae; Mixed (Non competitive and competitive),30. Inhibition constant against Beta-galactosidase from Aspergillus oryzae; Mixed (both competitive and non-competitive),31. Inhibition of beta-galactosidase in bovine liver after 30 mins by spectrophotometric analysis,32. Inhibitory activity towards Beta-galactosidase from Jack bean,33. Inhibitory activity towards Beta-galactosidase from Jack bean,34. Inhibitory activity towards Beta-galactosidase from Bovine liver,35. Inhibitory activity towards Beta-galactosidase from Bovine liver,36. Inhibitory activity towards Beta-galactosidase from Bovine liver,37. Inhibition of bovine liver beta-galactosidase assessed as inhibition of p-nitrophenol release by spectrophotometry,38. Inhibition of bovine liver beta-galactosidase,39. Inhibition of human beta galactosidase,40. Inhibition of bovine liver beta-galactosidase,41. Inhibition of beta-galactosidase,42. Inhibition of bovine liver beta-galactosidase,43. Inhibition of bovine liver beta-galactosidase by spectrometry,44. Inhibition of human lysosomal beta-galactosidase assessed as inhibition of hydrolyzed 4-methylumbelliferone production after 30 mins by luminescence spectrophotometry,45. Inhibition of bovine kidney beta-D-galactosidase after 10 to 20 mins,46. Inhibition of bovine liver beta-glucosidase/beta-galatosidase,47. Inhibition of bovine liver beta-galactosidase assessed as production of p-nitrophenol by spectrophotometry,48. Inhibition of bovine liver beta-galactosidase,49. Inhibition of lactase in mouse intestinal input by glucose release assay,50. Inhibition of beta-galactosidase,51. Inhibition of bovine liver beta-galactosidase assessed as p-nitrophenol release after 30 mins by spectrophotometry,52. Inhibition constant against beta-galactosidase enzyme of jack bean was reported,53. Concentration required to inhibit beta-galactosidase enzyme by 50% from jack bean was reported,54. Inhibition of beta-galactosidase from Aspergillus oryzae,55. Inhibitory activity against beta-galactosidase from bovine liver,56. Inhibition of beta-galactosidase from jack beans,57. Inhibition of beta-galactosidase from Aspergillus oryzae,58. Compound was evaluated for inhibition of beta-galactosidase from aspergillus oryzae (sigma G 7256).,59. Inhibition of bovine liver beta-galactosidase using p-nitrophenyl-glycoside as substrate by spectrophotometric method,60. Inhibition of human lysosomal beta-galactosidase using 4-MU beta-gal as substrate incubated for 96 hrs by fluorescence assay,61. Inhibition of bovine liver beta-galactosidase,62. Inhibition of bovine liver beta-galactosidase using 4-nitrophenyl-beta-D-galactopyranoside as substrate preincubated up to 5 mins followed by substrate addition measured up to 10 mins,63. Inhibition of human beta-galactosidase expressed in mouse fibroblasts using 4-methylumbelliferone -conugated beta-D-galactoside as substrate incubated for 30 mins at pH 4.5 followed by substrate addition by fluorescence analysis,64. Inhibition of Agrobacterium sp. beta-galactosidase,65. Inhibition of Aspergillus oryzae beta-galactosidase using 2-chloro-4-nitrophenyl beta-Dgalactopyranoside as substrate by spectrophotometry,66. Inhibition constant(Non competitive) of compound against Beta-galactosidase from Aspergillus niger,67. Inhibition constant (Non competitive) of compound against Beta-galactosidase from Aspergillus niger,68. Inhibition constant (Competitive) against Beta-galactosidase from Aspergillus niger was tested at a dose of 1 mM,69. Inhibitor concentration against Beta-galactosidase from Aspergillus niger was tested at a dose of 1 mM,70. Inhibitor concentration against Beta-galactosidase from Aspergillus niger,71. Inhibitory activity against Beta-D-galactosidase of Aspergillus niger expressed as Ki,72. Inhibitory concentration against Beta-D-galactosidase of Aspergillus niger,73. Inhibition constant (Competitive) against Beta-galactosidase from Escherichia coli,74. Inhibitor concentration against Beta-galactosidase from was Escherichia coli,75. Inhibitory activity towards Beta-galactosidase from Aspergillus niger,76. Inhibitory activity towards Beta-galactosidase from Aspergillus niger,77. Inhibition of Aspergillus oryzae beta-galactosidase by spectrometry,78. Inhibition of Escherichia coli beta-galactosidase assessed as inhibition of nitrophenolate release by spectrophotometry,79. Inhibition of Escherichia coli beta-galactosidase at 1 mM,80. Inhibition of Escherichia coli beta-galactosidase,81. Inhibition of Escherichia coli beta-galactosidase by Lineweaver-Burke plot analysis,82. Concentration required to inhibit beta-galactosidase enzyme by 50% from Escherichia coli was reported,83. Inhibition of beta-galactosidase from Aspergillus niger,84. Inhibition of beta-galactosidase from Aspergillus niger,85. Compound was tested for inhibition of beta-galactosidase from aspergillus niger.,86. Compound was evaluated for its Michaelis-Menten constant against E-coli Beta-galactosidase,87. Compound was evaluated for its binding affinity towards E-coli Beta-galactosidase,88. Compound was evaluated for its binding affinity towards Beta-galactosidase,89. Inhibition of Escherichia coli beta-galactosidase using o-nitrophenyl beta-D-galactopyranoside after 10 to 30 mins by spectrophotometric method,90. Inhibition of Escherichia coli beta-galactosidase,91. Inhibition of Escherichia coli lacZ beta-galactosidase using 4-nitrophenyl-beta-D-galactopyranoside as substrate preincubated up to 5 mins followed by substrate addition measured up to 10 mins,92. Competitive inhibition of Escherichia coli beta-galactosidase assessed as p-nitrophenyl-beta-D-galactopyranoside substrate hydrolysis by UV/Vis spectroscopy,93. Inhibition of Aspergillus oryzae beta-galactosidase using oNP-beta-Gal as substrate assessed as release of o-nitrophenol incubated for 30 mins by spectrophotometric analysis,94. Dose response counterscreen for EBI2 assay utilizing the enzyme, b-galactosidase,95. Dose Response confirmation of uHTS hits from a small molecule antagonists of the CXCR6 receptor in a screening assay,96. HTS Dose response counterscreen for assays utilizing the enzyme, b-galactosidase,97. Activity of Cat A assessed as hydrolysis,98. Inhibition of recombinant CatA using [14C]GS-7340 substrate,99. Inhibition Assay: The activated cathepsin A was diluted in assay buffer (25 mM MES, pH 5.5, containing 5 mM DTT) and mixed with the test compound (dissolved in assay buffer containing (v/v) 3% DMSO) or, in the control experiments, with the vehicle in a multiple assay plate. After incubation for 15 min at room temperature, as substrate then bradykinin carrying an N-terminal (R)Bodipy FL (4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionyl) label (JPT Peptide Technologies GmbH; dissolved in assay buffer) was added to the mixture. The final concentration of cathepsin A was 833 ng/ml and the final concentration of labeled bradykinin 2 inverted question markM. After incubation for 15 min at room temperature the reaction was stopped by the addition of stop buffer (130 mM 2-(4-(2-hydroxy-ethyl)-piperazin-1-yl)-ethanesulfonic acid, pH 7.4, containing (v/v) 0.013% (R)Triton X-100, 0.13% Coating Reagent 3 (Caliper Life Sciences), 6.5% DMSO and 20 inverted question markM ebelact,100. Inhibition of cathepsin A (unknown origin) using MCA-RPPGFSAFK-Dnp as substrate preincubated for 10 mins followed by substrate addition measured for 30 mins by spectrophotometric analysis,101. Inhibition of recombinant cathepsin A (unknown origin) using Mca-Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)-OH as substrate incubated with enzyme for 5 mins prior to substrate challenge for 2 hrs by spectrofluorometer analysis,102. Inhibition of human recombinant Myc-His10-tagged cathepsin A expressed in baculovirus infected Sf
ACTIVITYSubstance BioActivity: 1 Active, 1 Tested Substance BioActivity: 1 Active, 3 Tested Substance BioActivity: 2 Active, 1 Activity <= 1 µM, 7 Tested Substance BioActivity: 5 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 3 Tested Substance BioActivity: 1 Tested Substance BioActivity: 2 Tested Substance BioActivity: 3 Tested Substance BioActivity: 1 Tested Substance BioActivity: 1 Active, 12 Tested Substance BioActivity: 1 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 3 Active, 6 Tested Substance BioActivity: 6 Active, 1 Activity <= 1 µM, 7 Tested Substance BioActivity: 4 Tested Substance BioActivity: 3 Active, 3 Activity <= 1 µM, 3 Tested Substance BioActivity: 9 Active, 4 Activity <= 1 µM, 9 Tested Substance BioActivity: 1 Tested Substance BioActivity: 1 Active, 2 Tested Substance BioActivity: 3 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 1 Active, 1 Tested Substan